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1  Summary 
The 2015 Nobel Prize in Physiology or Medicine was 
awarded to Professor Tu YouYou for her key contributions 
to the discovery of artemisinin. Artemisinin has saved mil-
lions of lives and represents one of the significant contribu-
tions of China to global health. Many scientists were in-
volved in the previously unknown 523 Project, and the No-
bel Prize given to a single person has not been without con-
troversy.  Here we summarize some key events in the 523 
Project and present our views on the Award to help the pub-
lic better understand the rationale of the Nobel Committee’s 
decision, the significance of the discovery, and current is-
sues related to artimisinin in treating malaria. 
2  Introduction 
The discovery of artemisinin dramatically changes the 
landscape to combat malaria and leads to a paradigm shift in 
antimalarial drug development. According to a recent WHO 
report, 97 countries have ongoing malaria transmission, and 
an estimated 3.4 billion people are at risk of malaria, of 
whom ~1.2 billion are at high risk (http://www. 
who.int/malaria/publications/world_malaria_report_2014/en
/). The good news is that between 2000 and 2012, the ma-
laria incidence rates were reduced by 25% globally, and the 
global malaria mortality rate was reduced by 42% during 
the same period. Many countries are now on track for de-
claring malaria-free status. Artemisinin and its derivatives 
have played a key role in malaria related mortality. Ac-
cording to a recent estimate, approximately 22% of the 663 
million averted clinical cases were due to the use of arte-
misinin combination therapies (ACTs) [1]. 
Artemisinin represents a new class of antimalarial drugs, 
which leads to two paradigm shifts in antimalarial research 
and therapy. The first one is the change from quino-
line-based antimalarial drugs to artemisinin-based therapies 
due to the emergence of parasites resistant to quinoline 
drugs. Currently, ACTs are the drugs recommended by 
WHO for treating the deadly Plasmodium falciparum infec-
tions and are being used worldwide (http://www. 
who.int/malaria/publications/atoz/9789241549127/en/).  
The second paradigm shift is the change of research di-
rection in antimalarial drug development. Artemisinin and 
its derivatives are in a new class of antimalarial agents with 
unique structure (1,2,4-trioxane peroxide pharmacophore), 
which has become a new direction for antimalarial drug 
development. For example, some of the most promising 
drugs under clinical trials, including OZ277 and OZ439, are 
synthetic peroxides with key structures similar to artemis-
inin [2,3]. Additionally, research related to artemisinin has 
been a hot topic in malaria and other fields such as antiviral 
and anticancer treatments in the past 15 years [4]. A search 
of PubMed for key word ‘artemisinin’ identified 2,869 arti-
cles published in the last three years. The discovery of ar-
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timisinin changes the direction on how we treat malaria and 
how we develop and search for new antimalarial drugs. The 
impacts on global health and the paradigm shifts in antima-
larial drug research are the key factors that the Nobel Com-
mittee considered when they evaluated all the nominations.  
3   A brief history of artemisinin discovery 
Artemisinin was discovered during the Chinese “Cultural 
Revolution” in the 1970s, at a time when scientific research 
was not allowed, and results from ongoing projects such as 
the 523 Project were not published. In response to a request 
from the Vietnam government for help on malaria treat-
ment, the Chinese government launched a secret operation 
called 523 Project. On May 23 (523), 1967, a meeting was 
held in the Beijing to discuss plans for the search, which 
officially launched the project. Professor Tu was brought 
into the project in January, 1969 when Mr. Bai BingQiu and 
Mr. Zhang JianFang (523 Project directors) visited the In-
stitute of Chinese Materia Medica (ICMM) and asked for 
help. Professor Tu became involved in the 523 Project after 
the visit and was designated as a team leader to search for 
Chinese herb recipes having antimalarial activities. 
Professor Tu’s group started with a search for recipes 
that had been used to treat fever. They searched more than 
2,000 recipes and compiled 640 recipes for further evalua-
tion within three months. They then looked at the individual 
plant names that had high frequencies of appearance in the 
recipes. A plant called ‘Qinghao’ or Artemisia annua was 
one of the plants that appeared in the recipes frequently. 
Professor Tu’s group tested extracts from more than 100 
plants on rodent malaria parasite Plasmodium berghei. An 
extract from A. annua had ~68% inhibition rate initially, but 
the activity was not stable, varying from 12%40% inhibi-
tion in subsequent repeats. The variation in antimalarial 
activity could be due to many factors, including (as reported 
by Professor Tu in the 1972 presentation to the scientists in 
the Project) geographic origins of the plant, seasonal varia-
tion, different parts of the plant (leaves or stem) and the 
methods used in extraction. One day, Professor Tu was 
reading some recipes written by Ge Hong ~1700 years ago. 
In one of his recipes, Ge Hong described how to obtain 
‘juice’ from Qinghao (A. annua) plant to treat fever using 
cold water, instead of the traditional methods of boiling 
herbs for preparing Chinese medicines. Professor Tu sud-
denly realized that high temperature could be the cause of 
instability in antimalarial activity they experienced. The 
second hint Professor Tu had from Ge Hong’s description 
was that the plant leaf was likely the part having the most 
activity because the ‘juice’ could be obtained from the 
leaves much easier than other parts of the plant. She decided 
to use ether, replacing ethanol, to extract the active ingredi-
ents from the plant leaves and obtained sample #191 that 
could inhibit rodent malaria (October, 1971) and monkey 
malaria with 100% activity in December, 1971. Professor 
Tu presented her work at a meeting held in Nanjing on 
March 8, 1972. Her results were exciting, and the leadership 
of the 523 Project decided that she should conduct a clinical 
trial in the same year. In August 1972, Professor Tu led a 
clinical trial team to Hainan Island and tested her extracts 
on 21 patients, achieving 95%100% efficacy after taking 
the medicine herself to evaluate the safety of the extract. 
Professor Tu reported the results from the clinical trials in a 
meeting held in November 17, 1972. The exciting results 
led to a large-scale, countrywide effort to extract large 
quantities of the pure ingredient (or arteimisinin crystal) to 
determine its structure and to chemically synthesize arte-
misinin involving a large number of scientists from many 
institutions. These key events are supported by documents 
or presentations of the 523 Project provided by Professor 
Tu.  
4  Professor Tu’s major contributions in the 
discovery of artemisinin 
4.1  Professor Tu played a critical role in the discovery 
of artemisinin. Her major contributions are:  
(1) Bringing the plant into the 523 Project. Hundreds of 
scientists were involved in the 523 Project; however, Pro-
fessor Tu was the person who brought A. annua into the 523 
Project or re-discovered the plant. In a 523 meeting sum-
mary dated June 1, 1971, the scientists of the 523 Project 
discussed progress, including the identification of different 
herbs/plants with antimalarial activities, but did not mention 
the A. annua plant (Figure 1A), suggesting that they were 
NOT aware of the antimalarial activity of the A. annua plant 
at that time (or it was not among their priorities). Nine 
months later on March 8, 1972, Professor Tu described her 
discovery of extract from A. annua and showed that the 
extract was effective in treating P. berghei at another 523 
meeting held in Nanjing (Figure 1B). These two classified 
523 Project documents clearly showed that Professor Tu 
was the person who brought A. annua into the 523 Project.  
(2) Professor Tu discovered a method to extract active 
ingredient. In her presentation dated March 8, 1972, Pro-
fessor Tu described a procedure for extracting stable and 
active antimalarial extract (neutral portion). They replaced 
ethanol (boiling point 78oC) with ether (boiling point 35oC) 
in the extraction, which greatly improved the stability of the 
active ingredient. Other groups in the 523 Project were able 
to obtain high quality of artemisinin crystals after hearing 
her report. There were two letters sent to Tu’s institute 
(Yunnan Institute of Pharmacy and Shangdong Institutes of 
Parasitology, respectively) in 1973 that expressed gratitude 
for sharing information on artemisinin extraction. A copy of 
each letter can be found in the book titled “Qinghao and 
Qinghaosu Derivative Drugs” (page 40) [5]. Therefore,    
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Figure 1  Images of partial 523 Project meeting summary and Professor Tu’s 1972 presentation. A, The meeting summary of June 1, 1971 listed seven 
Chinese herbs that were the focuses at that time, but no mention of Qinghao plant. B, A paragraph of Professor Tu’s 1972 (March 8) presentation describing 
results of 95%100% efficacy from rodent and monkey experiments using the neutral portion of her ether extract (with permission from the document pro-
vider). 
Professor Tu was the person who discovered an efficient 
method for extracting the active ingredient from the A. an-
nua plant. 
(3) Professor Tu conducted the first clinical trial of Arte-
misia extract in human patients. Professor Tu also led a 
team to Hainan and conducted the first clinical trial in hu-
mans in August 1972. They tested the drug in 11 cases of 
Plasmodium vivax, 9 cases of Plasmodium falciparum, and 
1 case of a mixed infection. All the patients quickly re-
turned to normal temperature from 40oC, and many were 
negative of parasites in the blood smear. The results were 
better than those of the control group given chloroquine. 
Later, they tested another 9 cases in Beijing and obtained 
similar results. She wrote a report and presented the results 
in a 523 Project meeting held on November 17, 1972 [5], 
setting off a large-scale effort to isolate the active ingredi-
ent . This also was the time when other scientists received 
instructions to work on artemisinin related projects. Thus, 
Professor Tu was the person who conducted the first suc-
cessful clinical trial in human. 
(4) Isolation of active ingredient for structural studies. 
Following the demonstration of antimalarial activity, her 
group continued to isolate the active ingredient. They ob-
tained a white crystal that had melting point of 156157oC 
with molecular weight of 282 in November 8, 1972, which 
they named Qinghaosu. They showed that 50100 mg kg1 
dosages could cure rodent malaria parasites. The isolation 
of the crystal allowed further investigation of its chemical 
structure. She coordinated with scientists in Beijing and 
Shanghai and played a role in determining the structure us-
ing the crystal they obtained. 
(5) The discovery of dihydroartemisinin. Professor Tu 
also discovered dihydroartemisinin that greatly improved 
water solubility.  
Because of her many critical contributions, the Chinese 
Ministry of Health issued a ‘New Drug Certificate for Ar-
teminisin’ to her institute in 1986 [5], suggesting official 
recognition of her discovery. Her institute also received 
certificate of new drug for dihydroartemisinin. 
4.2  National and international recognition of her con-
tributions in the discovery of artemisinin and deriva-
tives. 
Because of her critical contributions and achievements in 
the discovery, Professor Tu received numerous awards from 
the Chinese government and private organizations world-
wide, including the National Scientific Discovery Award for 
the Antimalarial Drug—Qinghaosu by the Ministry of Sci-
ence and Technology in 1979; the National Model Worker 
by the State Council in 1995; the Outstanding Scientific 
Achievement Award by Qiu Shi Science and Technologies 
Foundation of Hong Kong in 1996; Achievement Award in 
New China by the Ministry of Health in 1997; Prince Ma-
hidol Award, Prince Mahidol Award Foundation, Thailand 
in 2003; Award for Development of Chinese Materia 
Medica, Cyrus Chung Ying Tang Foundation in 2009; the 
Albert Lasker Award for Clinical Medical Research in 
2011; GlaxoSmithKline Outstanding Achievement Award 
in Life Sciences in 2011;  The Warren Albert Foundation 
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Prize in 2015; the 2015 Nobel Prize in Physiology or Medi-
cine. 
4.3  Other evidence supporting Professor Tu’s key role 
in the discovery 
As mentioned above, Professor Tu was one of the 10 people 
who received an award from the Qiu Shi Science and 
Technologies Foundation of Hong Kong for contributions to 
the 523 Project in 1996. She was described as “the inventor 
of new antimalarial drugs artemisinin and dihydroartemis-
inin”. 
Professor Li GuoQiao (a participant of the 523 Project 
and one of the 10 Qiu Shi Awardees) confirmed that Tu was 
the first person who discovered arteminisn in his interview 
with news media after the Lasker Award presented to Pro-
fessor Tu in 2011 (http://gzdaily. dayoo.com/html/2011- 
09/29/content_1489532.htm).  
The following is a question to Professor Li GuoQiao 
during an interview after Tu’s Lasker Award: “If you were 
awarded with the Lasker Award, who else should receive 
the Award too?” Professor Li said he filled in Tu YouYou 
first, Mrs Luo ZheYuan, the second. Similarly, another Qiu 
Shi Awardee Mr. Liang JuZhong said: “First of all, I want 
to congratulate Tu YouYou for winning the Award. As the 
discoverer of artemisinin, she deserved the honor” during an 
interview with reporter. 
Professor Zhou WeiShan (a chemist who played a key 
role in structure determination and synthesis of artemisinin 
and also one of the Qiu Shi Awardees), interviewed by 
Chinese reporters some years ago, also credited the key 
contribution to Professor Tu (http://emuch.net/html/ 
200903/1242552.html). 
The following are quotations and answers during Pro-
fessor Zhou WeiShan’s interview with Chinese “Science 
Times” in December 2009. The original article was in Chi-
nese. We include a brief translation: Tu YouYou joined the 
523 Project as a team leader in January 1969. The other 
scientists screened over 40,000 herbs and compounds, but 
no satisfactory results. Tu YouYou decided to search tradi-
tional Chinese medicinal books and interview Chinese tra-
ditional medicine doctors. She compiled more than 640 
recipes, many of them contained Qinghao. The initial results 
were not satisfactory, and she read more traditional medici-
nal books. Some sentences from Ge Hong’s writing attract-
ed her attention ‘A bunch of Qinghao, squeeze in two liters 
of cold water, and drink the juice’. This description was 
different from the traditional methods of boiling Chinese 
herbs. She decided to use ether at 60oC boiling point (as 
cited in the interview) for extraction. She observed 100% 
inhibition on October 4, 1971. On March 1972, Tu YouYou 
reported her results at a 523 meeting held in Nanjing. In 
1973, the activity of artemisinin crystal was verified in 
Yunnan region. The 523 Office decided to name the crystal 
Qinghaosu and to develop it as a new drug. In 1973, the 
Institute of Chinese Materia Medica obtained Qinghao 
crystal and was looking for chemists who could help deter-
mine the structure. Mr. Zhou was not the first person they 
contacted. Mr Zhou’s description matches the history de-
scribed above. 
5  The emergence of artemisinin tolerant para-
sites 
Due to the large-scale use of artemisinin in recent years, P. 
falciparum parasites that are potentially resistant (or more 
tolerant) to the drug have been reported in countries in 
Southeast Asia [6,7]. Although the classical drug resistant 
parasites that can survive constant drug pressure have not 
been found, parasites that can survive longer in patients 
after standard ACT treatments are reducing parasite cure 
rate and patient recovery. Artemisinin has a short half-life in 
vivo, and it is used for treating malaria infections, not for 
prophylaxis. Professor Tu has been trying to raise public 
awareness of this serious issue for years.   
6  Credits and controversies 
There have been many controversial issues associated with 
credits and contributions to the 523 Project and the discov-
ery of artemisinin. It is a fact that a large number of people 
took part in and contributed to the project, including lead-
ership from the People’s Liberation Army. All later work 
was based on her initial demonstration of active ingredient 
from the Qinghao plant. We can only imagine what the fu-
ture would have held if Professor Tu had not presented her 
results at the March 8 (1972) 523 meeting in Nanjing. The 
project might have focused on other leads instead of the 
Qinghao plant. In this sense, the project actually greatly 
benefited from her discovery. Without her initial presenta-
tion on March 8, 1972, there would have been no other 
Qinghao crystals obtained by other institutes, no work on 
chemical structure, no artemisinin derivatives synthesized, 
and no clinical trials. Often when multiple people are in-
volved in an important research development, The Nobel 
Prize Committee recognizes only the individual who made 
the seminal discovery that led to the development.  For 
example, the Nobel Prize went to Harald Zur Hausen for the 
discovery of the papillomavirus in cervical cancer and not 
to others who later developed the vaccine.   
7  Conclusions 
There is no doubt that Professor Tu is the first person who 
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brought the A. annua into the 523 Project, the first person 
who obtained the active ingredient (extract and crystal), and 
the first person who demonstrated antimalarial activity in 
humans. The impact of artemisinin on public health is im-
mediate and tremendous. Millions of lives have been saved 
by the use of artemisinin. Additionally, the discovery of 
artemisinin has led to paradigm shifts in antimalarial re-
search and therapy. There are few scientific discoveries that 
have the same scale and instant impacts on public health, 
human productivity, and scientific research as artemisinin 
has!  
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